The reiteration of a 'Market Outperform' rating and the maintenance of a $19 price target by a reputable analyst like Jason Butler from JMP Securities could instill confidence in investors and potentially lead to a positive short-term impact on Cormedix's stock price. Analyst ratings, especially those that are positive and come from well-regarded financial institutions or analysts, can influence investor sentiment and stock prices in the short term.